Frequently Asked Questions

The ReVive® HP System is an all-in-one extracorporeal blood purification platform designed for hemoperfusion. It is used to rapidly remove drugs, toxins, and inflammatory mediators (cytokines) directly from the bloodstream in veterinary patients.

AimaLojic® provides a fully integrated solution—pump, columns, tubing, and protocols—specifically designed for veterinary use, with fast setup, scalable treatment volumes, and semi-selective adsorption that removes harmful substances while preserving essential blood components.

No. The ReVive® HP System is not a dialysis machine. Hemoperfusion differs from dialysis in that it removes substances directly from the blood through adsorption technology, whereas dialysis removes substances across a membrane using diffusion. The ReVive® HP System is designed specifically to deliver hemoperfusion therapy.

ToxiClear® is designed to adsorb a wide range of drugs and toxins, making it ideal for acute intoxications and poisonings.

CytoClear® is designed to reduce circulating cytokines (inflammatory mediators) and blood dysregulation associated with critical illness.

Yes. AimaLojic® columns use semi-selective adsorption—designed to remove harmful substances while minimizing removal of beneficial proteins, electrolytes, and nutrients.

Each column is single-use and designed for a defined treatment duration. Actual runtime depends on clinical goals, flow rate, and patient size.

The ReVive® HP System is designed to treat a wide range of patient sizes, from small dogs/cats to large-breed and specialty referral cases, using appropriate circuit configurations and flow rates.

Anesthesia is not inherently required for hemoperfusion, but sedation or anesthesia may be used depending on patient stability, catheter placement, and clinician judgment.

When used according to protocol, hemoperfusion has a strong safety profile. Patients are continuously monitored for hemodynamics, anticoagulation status, and circuit performance during treatment.

Potential risks include hypotension, bleeding related to anticoagulation, and vascular access complications, similar to other extracorporeal therapies. Proper patient selection and monitoring mitigate these risks.

No. The ReVive® HP System is designed to be intuitive and includes comprehensive training for veterinary teams without prior extracorporeal therapy experience.